Reports
Sale
North America Respiratory Inhalers Market Size, Analysis: By Product: Dry Powder Inhalers, Metered Dosed Inhalers, Soft Mist Inhalers, Nebulizers; By Technology: Conventional Inhalers, Smart Inhalers; By Indication: Asthma, COPD; By End User: Hospitals, Clinics, Homecare Settings, Others; Regional Analysis; Supplier Landscape; 2024-2032
North America Respiratory Inhalers Market Outlook
North America respiratory inhalers market size is expected to grow at a CAGR of 5.90% during the forecast period of 2024-2032, driven by the rising prevalence of respiratory diseases along and the development of advanced inhaler devices in the region.
Key Takeaways
- It is estimated that around 15.7 million Americans which accounts for 6.4% of the population have been diagnosed with chronic obstructive pulmonary disease (COPD). This growing patient base is expected to directly impact market demand in the region.
- One of the major North America respiratory inhalers market trends is the rise in strategic partnerships among the key market players to improve the accessibility of their inhaler devices. In June 2023, Teva Pharmaceuticals Industries Ltd. partnered with Phil Inc. to improve the accessibility of their Digihaler products for asthma patients using the PhilRx Patient Access Platform.
- The favorable regulatory environment in the region is likely to boost market size. In January 2023 , the FDA approved AstraZeneca's rescue inhaler, Airsupra. The pressurized metered-dose inhaler for adult use offers a treatment option that can both manage the symptoms and the underlying inflammation during an asthma attack.
North America Respiratory Inhalers Market Analysis
Respiratory inhalers are portable, hand-held devices that can deliver medication directly to the lungs. These devices help in the treatment and management of chronic obstructive pulmonary disease (COPD) and asthma symptoms. Administration through inhalation offers a distinct advantage by ensuring that the maximum concentration of the medicine reaches the target tissue. Thus, the ability of these inhaler devices to deliver the highest potential therapeutic effect of the drug coupled with advancements in inhaler technology is expected to propel the North America respiratory inhalers market demand in the forecast period.
In North America, various respiratory conditions are becoming increasingly common, driven by factors such as smoking, air pollution, and the growing aging population. It is estimated that around 15.7 million Americans accounting for 6.4% of the population have been diagnosed with chronic obstructive pulmonary disease (COPD). Moreover, it is reported that COPD ranks as the fourth leading cause of death in the United States. Since inhaled medications stands as the primary treatment for COPD, along with the inhaler technique necessary to boost the medication efficacy, the demand for respiratory inhalers is likely to witness a surge in coming years. Moreover, it is further fuelled by the growing patient base in the region.
Several leading market players are entering into strategic partnerships to improve the accessibility of their inhaler device portfolios, which is anticipated to contribute to North America respiratory inhalers market growth. For instance, in June 2023, Teva Pharmaceuticals’ partnered with a United States-based health-tech startup Phil Inc. to facilitate increased access to their Digihaler products (the first smart inhaler system that records objective inhaler data) using the PhilRx Patient Access Platform. The patient-centric technology solution by Phil Inc., offers complete visibility into the entire prescription lifecycle, streamlining prescription filling and medication management for asthma patients. Integration of such technologically advanced platforms is expected to enhance the consumer experience as well as improve patient outcomes, thereby elevating the market value.
The favorable regulatory environment is facilitating the introduction of new inhaler products in the region, which is expected to boost the North America respiratory inhalers market share. In January 2023 , the United States Food and Drug Administration (FDA) approved a first-in-class rescue inhaler Airsupra, co-developed by AstraZeneca and Avillion LLP (a drug development company). The combination therapy received FDA approval based on the positive results demonstrated in the phase III trials called MANDALA and DENALI. The pressurized metered-dose inhaler for adult use contains both albuterol and budesonide, thus, it provides a treatment option that can manage the symptoms as well as the underlying inflammation during an asthma attack.
North America Respiratory Inhalers Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product | Dry Powder Inhalers, Metered Dosed Inhalers, Soft Mist Inhalers, Nebulizers, (Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers) |
| Type | Conventional Inhalers, Smart Inhalers |
| Indication | Asthma, COPD |
| End User | Hospitals, Clinics, Homecare Settings, Others |
| Countries | United States of America, Canada |
North America Respiratory Inhalers Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AstraZeneca Plc
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Cipla Ltd
- GSK Plc (GlaxoSmithKline Plc)
- Koninklijke Philips NV
- OMRON Corp
- PARI Respiratory Equipment, Inc.
- Teva Pharmaceutical Industries Ltd
- OPKO Health, Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Technology |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Respiratory Inhalers Market Overview
3.1 North America Respiratory Inhalers Market Historical Value (2017-2023)
3.2 North America Respiratory Inhalers Market Forecast Value (2024-2032)
4 North America Respiratory Inhalers Market Landscape*
4.1 North America Respiratory Inhalers Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Respiratory Inhalers Market: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
5 North America Respiratory Inhalers Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Respiratory Inhalers Market Segmentation (2017-2032)
6.1 North America Respiratory Inhalers Market (2017-2032) by Product
6.1.1 Market Overview
6.1.2 Dry Powder Inhalers
6.1.3 Metered Dosed Inhalers
6.1.4 Soft Mist Inhalers
6.1.5 Nebulizers
6.1.5.1 Jet Nebulizers
6.1.5.2 Ultrasonic Nebulizers
6.1.5.3 Mesh Nebulizers
6.2 North America Respiratory Inhalers Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Conventional Inhalers
6.2.3 Smart Inhalers
6.3 North America Respiratory Inhalers Market (2017-2032) by Indication
6.3.1 Market Overview
6.3.2 Asthma
6.3.3 COPD
6.4 North America Respiratory Inhalers Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Clinics
6.4.4 Homecare Settings
6.4.5 Others
6.5 North America Respiratory Inhalers Market (2017-2032) by Countries
6.5.1 Market Overview
6.5.2 United States of America
6.5.3 Canada
7 United States of America Respiratory Inhalers Market (2017-2032)
7.1 United States of America Respiratory Inhalers Market (2017-2032) by Product
7.1.1 Market Overview
7.1.2 Dry Powder Inhalers
7.1.3 Metered Dosed Inhalers
7.1.4 Soft Mist Inhalers
7.1.5 Nebulizers
7.1.5.1 Jet Nebulizers
7.1.5.2 Ultrasonic Nebulizers
7.1.5.3 Mesh Nebulizers
7.2 United States of America Respiratory Inhalers Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Conventional Inhalers
7.2.3 Smart Inhalers
7.3 United States of America Respiratory Inhalers Market (2017-2032) by Indication
7.3.1 Market Overview
7.3.2 Asthma
7.3.3 COPD
7.4 United States of America Respiratory Inhalers Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals
7.4.3 Clinics
7.4.4 Homecare Settings
7.4.5 Others
8 Canada Respiratory Inhalers Market (2017-2032)
8.1 Canada Respiratory Inhalers Market (2017-2032) by Product
8.1.1 Market Overview
8.1.2 Dry Powder Inhalers
8.1.3 Metered Dosed Inhalers
8.1.4 Soft Mist Inhalers
8.1.5 Nebulizers
8.1.5.1 Jet Nebulizers
8.1.5.2 Ultrasonic Nebulizers
8.1.5.3 Mesh Nebulizers
8.2 Canada Respiratory Inhalers Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Conventional Inhalers
8.2.3 Smart Inhalers
8.3 Canada Respiratory Inhalers Market (2017-2032) by Indication
8.3.1 Market Overview
8.3.2 Asthma
8.3.3 COPD
8.4 Canada Respiratory Inhalers Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals
8.4.3 Clinics
8.4.4 Homecare Settings
8.4.5 Others
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Beximco Pharmaceuticals Ltd.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Boehringer Ingelheim International GmbH
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Cipla Ltd
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 GSK Plc
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Koninklijke Philips NV
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 OMRON Corp
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 PARI Respiratory Equipment, Inc.
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Teva Pharmaceutical Industries Ltd
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 OPKO Health, Inc
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 AstraZeneca Plc
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Respiratory Inhalers Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.90% during the forecast period of 2024-2032, driven by the rising prevalence of respiratory diseases in the region.
The development of advanced inhaler devices and advancement in the healthcare infrastructure are fuelling the demand for the market.
One of the significant trends in the market is the rise in strategic partnerships among the key market players to improve the accessibility of their inhaler devices. In June 2023, Teva Pharmaceuticals Industries Ltd. partnered with Phil Inc. to improve the accessibility of their Digihaler products for asthma patients using the PhilRx Patient Access Platform.
Based on the product, the market is segmented into dry powder inhalers, metered dosed inhalers, soft mist inhalers, and nebulizers. The nebulizers are further bifurcated into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers.
By type, the market is divided into conventional inhalers and smart inhalers.
The market breakup by indication includes asthma and COPD.
End users of the market are hospitals, clinics, and homecare settings, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc (GlaxoSmithKline Plc), Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc., Teva Pharmaceutical Industries Ltd, and OPKO Health, Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER